Is the CEO Failing, or Is the Investment Thesis Wrong? A PE Sponsor Diagnostic
A missed investment case tells the board where the pain is. It does not tell the board what caused it.
Gaurav Shah|Managing Partner, Arete Ventures
The fastest way to make a bad portfolio problem worse is to diagnose it too quickly.
Revenue is below underwriting. EBITDA is behind case. The board starts questioning the CEO. That sequence feels logical because the CEO is accountable for the business. Accountability, however, does not identify causality.
The miss may come from an assumption that was wrong at entry. The market may have changed. The company may never have had the people, systems or capital required to deliver the plan. Management may have seen the problem and acted too slowly. The board may also have changed priorities, constrained investment or reopened decisions until execution lost momentum.
Those are different problems. They require different interventions.
Before discussing succession, I would rebuild the investment case. Then ask a more uncomfortable question: if another capable CEO had inherited the same company, resources, board and market conditions, how much better should the outcome reasonably have been?
A missed investment case is an outcome. It is not a diagnosis
A Missed Investment Case Is an Outcome, Not a Diagnosis
Accountability and causality are different questions
A portfolio CEO should be held accountable for enterprise performance. That does not mean every performance gap was created by the CEO.
This distinction matters because boards often collapse two questions into one. Who owns the result? What caused the result? The first is a governance question. The second is an investment question.
If the board gets the second question wrong, the intervention can make the asset worse. Replacing the CEO will not repair an impossible revenue assumption. Adding capital will not fix repeated poor management decisions. A new operating plan will not help if the sponsor continues to change priorities every quarter.
Start with the miss that can change returns
Do not begin with a broad judgment that "management is underperforming." Start with the part of the case that matters economically.
Is the problem volume, price, gross margin, labor productivity, integration, working capital, customer retention or capex? How large is the gap? When did it first appear? How much of the expected return depended on closing it?
This forces the board to move from impression to attribution. A missed initiative that has little impact on value does not deserve the same leadership response as a failure in the one commercial lever that underwrote the deal.
Rebuild the Underwriting Case Before You Judge Management
Which assumptions actually paid for the deal?
Every underwriting case has a few assumptions doing more work than the rest. Sometimes it is price. Sometimes it is volume, procurement savings, utilization, add-on synergies or working-capital release. The CEO assessment should begin there.
Take each material value lever and write down what had to be true for it to work. Which assumption came from market diligence? Which depended on management execution? Which required new capability, systems or capital after close?
Once those dependencies are visible, leadership performance becomes easier to judge. A CEO cannot be held to an outcome that required capabilities the sponsor never funded. The CEO can be held to account for failing to identify that constraint early or for not presenting a credible alternative.
Was the assumption wrong, or was execution poor?
The same symptom can have very different causes. A revenue miss may mean the market was smaller than diligence suggested. It may also mean the sales organization never changed. A margin miss may reflect a structurally higher cost base. It may also mean the procurement plan was never implemented.
The board should resist using one explanation for the whole company. A deal can contain both thesis error and execution failure. The useful work is to separate them by value lever.
Ask whether you would underwrite the asset the same way today
This is one of the cleanest checks available to an IC or board.
If the answer is no because a core market, margin or capital assumption no longer holds, the original plan needs to be re-underwritten before the CEO is judged against it. That does not excuse poor execution. It changes the baseline against which execution should be measured.
If the answer is yes, and the economic assumptions still look sound, the burden shifts toward operating execution. The question then becomes why the company failed to convert a still-valid thesis into results.
Observed outcome | Possible thesis problem | Possible execution problem |
|---|---|---|
Revenue below plan | Market growth, pricing power or addressable demand was overstated | Commercial execution, channel productivity or pricing discipline was weak |
Margin below case | Cost structure or achievable savings were misread | Procurement, footprint or productivity actions did not happen |
Add-on thesis stalls | Target availability or synergy assumptions were too optimistic | Integration discipline, systems or management capacity was inadequate |
Working capital worsens | Business model is structurally more cash intensive than assumed | Inventory, collections or operating controls were weak |
New geography disappoints | Market attractiveness was overestimated | Local leadership, route to market or launch execution failed |
Customer concentration persists | Diversification assumption was unrealistic | Commercial team failed to build the pipeline or change account mix |
Five Places I Would Look Before Calling It a CEO Problem
1. The thesis itself
Start with the assumptions that management cannot manufacture through effort. Market size, customer demand, price elasticity, structural cost, acquisition supply and exit conditions can all overwhelm a well-run operating plan.
The useful test is not whether the thesis has changed at all. Every investment evolves. The test is whether the change is large enough to invalidate the operating outcomes the CEO was hired to deliver.
2. External Conditions
A market shift can be real without becoming a blanket defense for management. Separate the shock from the response.
What changed outside the company? When did management know? Which parts were controllable? How quickly did the CEO revise price, cost, staffing, capex or commercial priorities?
A good CEO does not need to predict every external event. The more revealing evidence is what happens after the facts change.
3. The operating system beneath the CEO
Sponsors sometimes underwrite a value-creation plan as if the company already owns the machinery required to execute it.
It may not. The company may lack a real FP&A function, reliable customer data, integration capacity, pricing tools, middle management or the systems needed to run multiple sites. In that situation the board should ask two separate questions. Was the platform underbuilt? Did the CEO recognize that quickly enough and build what was missing?
A leadership diagnosis becomes stronger when it distinguishes inherited constraint from failure to repair the constraint.
4. The CEO's decisions once the problem became visible
Do not score the CEO on adjectives such as strategic, agile or resilient. Look at decisions. Did the CEO surface bad news early? Did priorities change when evidence changed? Were weak executives moved quickly enough? Was capital reallocated? Did the CEO stop initiatives that no longer made economic sense?
One poor decision may be noise. A pattern of late recognition, weak follow-through or repeated unwillingness to act is stronger evidence that leadership has become a constraint.
5. The sponsor and the board
The sponsor should be willing to examine its own contribution to the result.
Did the board approve a plan and then resist the capex needed to deliver it? Did deal and operating teams give management conflicting priorities? Were decisions repeatedly reopened? Did the sponsor insist on holding cost while also demanding accelerated growth? Was the CEO given accountability without clear authority?
None of this removes CEO accountability. It prevents the board from confusing governance friction with management incapability.
Use Counterfactuals, Not Hindsight
What would a stronger CEO have changed?
This question forces the board to define the value of replacement in operating terms.
Would a stronger CEO have changed the sales leader six months earlier? Repriced faster? Stopped an acquisition? Reduced fixed cost? Built a different management team? Escalated liquidity risk sooner?
If the board cannot identify the decisions that should have been different, it may be reacting to the outcome rather than diagnosing leadership.
What was knowable at the time?
Hindsight makes every miss look obvious. Board evaluation should reconstruct the information available when the decision was made.
What did management know? What did the sponsor know? What signals were ambiguous? Which risks were discussed but accepted? Which warnings were ignored?
A CEO who made a reasonable decision from incomplete information should be assessed differently from one who ignored clear evidence because changing course was uncomfortable.
What would have happened with the same CEO but a different operating system?
This counterfactual is useful when the asset has capability gaps.
If the CEO had received the agreed CFO hire, commercial resources, integration team or systems investment on schedule, would the outcome likely have changed? If yes, the board may have a platform problem mixed with a leadership problem. If no, the CEO case becomes harder to defend.
Repeated Decision Failure Is Stronger Evidence Than a Missed Number
Look for late recognition
The most damaging leadership pattern is often not getting the original forecast wrong. It is taking too long to admit that the forecast is wrong.
Sponsors should watch the lag between evidence appearing and management changing course. A recurring delay can consume more value than the original forecasting error.
Look at the management team the CEO tolerates
A CEO is partly revealed by the executives who remain in critical seats after the problems are known.
If a commercial, finance or operations leader is clearly below the level required by the thesis, how long does the CEO wait? What evidence is being sought? What is the cost of delay?
Repeated tolerance of known management weakness is more informative than a polished explanation of why the business missed plan.
Look at how bad news travels
The board should know whether it hears bad news early enough to act.
A CEO who surfaces a miss before the monthly pack is complete may create discomfort but preserve options. A CEO who waits for certainty can make the information cleaner and the intervention later.
In a finite hold period, the timing of truth matters.
Do Not Let the Sponsor Escape the Diagnosis
Conflicting priorities can manufacture management failure
A portfolio company cannot optimize every objective at once. Growth, margin, cash, integration and systems investment often compete for the same management capacity and capital.
If the board changes the hierarchy of those objectives every quarter, management can appear indecisive when the real problem is that the decision rule keeps moving.
Underfunded plans should be called underfunded plans
If the investment case requires a new ERP, commercial build-out, plant upgrade or management team, the board should be explicit about whether the capital was actually made available.
Targets without resources can still be useful as stretch goals. They should not later be presented as evidence of CEO failure without acknowledging the constraint.
Sponsor intervention has a point of diminishing returns
Active ownership is an advantage when it sharpens priorities, provides pattern recognition and accelerates decisions. It becomes a problem when management cannot tell who owns the final call.
If the CEO is asked to own the result, the board should be clear about which decisions the CEO can make without reopening the debate. Otherwise accountability becomes performative rather than operational.
Match the Intervention to the Failure Mechanism
What the evidence points to | What you would expect to see | Likely intervention |
|---|---|---|
Thesis is materially wrong | Core market, margin or synergy assumptions fail despite reasonable execution | Re-underwrite the plan and returns; reset value-creation priorities |
External conditions changed | Economics changed after close and management response is broadly sound | Adapt strategy, capital plan and expectations |
Operating system is inadequate | Capability, data, systems or resources cannot support the plan | Build the missing platform; set a deadline for evidence |
Functional leadership is weak | Problem is concentrated below CEO level | Upgrade CFO, COO, commercial or other key leadership |
CEO decisions are the constraint | Repeated late recognition, poor talent decisions or inability to adapt | Move into CEO intervention and succession analysis |
Governance is impairing execution | Conflicting direction, unclear authority or repeated board overrides | Reset decision rights and board operating cadence |
When the Diagnosis Is Mixed
A weak thesis can coexist with weak execution
An optimistic underwriting case does not absolve management. If the market is smaller than expected, the CEO can still be judged on how quickly the business resized cost, changed pricing, protected customers and revised the plan.
The board should avoid binary conclusions such as "thesis problem" or "management problem." Ask how much of the gap belongs to each and which part is still recoverable.
A capable CEO can become wrong for the revised plan
The CEO who was right for a five-year growth build may not be right for a two-year cash, repair and exit plan. That does not mean the original hire was wrong. The mandate may have changed.
This is why the leadership decision should be made against the forward case, not against the role specification signed at entry.
Sometimes the intervention should be narrower than CEO replacement
If the CEO diagnosis is mixed, strengthening one part of the system may create more value with less disruption.
A stronger CFO may solve information and cash-control problems. A COO may fix execution. A commercial leader may repair growth. A board change may improve governance. Sponsor support may close a capability gap that management cannot build quickly enough alone.
A search mandate should emerge from the diagnosis. The diagnosis should not be reverse-engineered to justify a search.
Re-Underwrite the CEO Against the Investment Case From Here
What must happen over the remaining hold?
Once the board has separated the causes of underperformance, rebuild the leadership requirement around the remaining value creation rather than the original plan.
What has to happen in the next 12 to 24 months? Which value levers are still available? Which have disappeared? What has become more important because the business is behind plan?
Which decisions will determine whether the revised case works?
Translate the revised case into a small number of executive decisions. The next stage may require pricing discipline, a management reset, integration, cost restructuring, refinancing, cash conversion or preparation for diligence.
Then evaluate the incumbent against evidence of making those decisions under comparable conditions. This is more useful than asking whether the CEO still fits the original competency profile.
What specifically would improve if the CEO changed tomorrow?
Before moving toward succession, the board should be able to answer this in plain language.
Which decisions become faster? Which capabilities arrive? Which management problems get resolved? Which part of the investment case becomes more achievable?
If the answer is vague, the diagnosis is probably not ready.
Six Questions Before Blaming or Replacing the CEO
# | Board/IC question |
|---|---|
1 | Which underwriting assumption is materially off plan? |
2 | Was that assumption wrong, did conditions change, or did execution fail? |
3 | Did management have the people, systems, capital and authority required to deliver the plan?
|
4 | What decisions did the CEO make once the problem became visible? |
5 | Did sponsor governance accelerate corrective action or make execution harder?
|
6 | What specifically should improve if the CEO is replaced? |
If those questions cannot be answered with evidence, I would be cautious about calling the situation a CEO problem. The board may still decide to change leadership. It should know what problem the change is intended to solve.
Diagnose the Failure Before Changing the Leader
The board owes loyalty neither to the CEO nor to the original underwriting case. It should follow the explanation that best fits the evidence, then choose the intervention most likely to improve the forward investment case.
A wrong diagnosis creates two forms of value leakage. The sponsor can spend a year coaching or supporting a CEO who will not change the outcome. Or it can replace leadership, lose transition time and discover that the same operating problem remains.
Good portfolio governance should make both errors harder.
For PE-Sponsors and Boards
For situations where the diagnosis points to a leadership change, the next step is to translate the revised investment case into the mandate and evidence required from the next executive. Arete applies this logic when evaluating leadership against the investment thesis and calibrating selected portfolio-company searches.
CLOSING PRINCIPLE
The quality of the succession decision is bounded by the quality of the diagnosis that comes before it.